HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites wiki
 

Vertex Pharmaceuticals NEWS

NFE/5.0en-USnews-webmaster@google.com2019 Google Inc.Sun, 20 Jan 2019 11:12:31 GMTGoogle News
Stocks With Rising Relative Price Strength: Vertex Pharmaceuticals  Investor's Business Daily

Vertex Pharmaceuticals (VRTX) saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 89 to 92. X. Error loading player:.

Investor's Business Daily
Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals  The Motley Fool

The U.S. Food and Drug Administration recently granted fast-track status to the first experimental new therapy from CRISPR Therapeutics (NASDAQ:CRSP).

The Motley Fool
5 Things to Expect for Vertex Pharmaceuticals in 2019  The Motley Fool

Vertex Pharmaceuticals (NASDAQ:VRTX) CEO Jeff Leiden likes accountability. That's why every year at the J.P. Morgan Healthcare Conference, he starts his ...

The Motley Fool
Vertex Pharmaceuticals (VRTX) Downgraded to “Market Perform” at Raymond James  Fairfield Current

Vertex Pharmaceuticals (NASDAQ:VRTX) was downgraded by research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a ...

Fairfield Current
Vertex teams up with Arbor Biotech in gene-editing therapies  Seeking Alpha

Vertex Pharmaceuticals (VRTX) will collaborate with Arbor Biotechnologies to discover novel proteins for gene-editing therapies for cystic fibrosis and fou.

Seeking Alpha
Vertex Pharmaceuticals Sees Its Composite Rating Rise To 97  Investor's Business Daily

Vertex Pharmaceuticals (VRTX) saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 94 to 97. X. Error loading player: No playable ...

Investor's Business Daily
New Buy Rating for Vertex Pharmaceuticals (VRTX), the Healthcare Giant  Smarter Analyst

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Vertex Pharmaceuticals (VRTX) yesterday. The company's shares closed yesterday at $175.85.

Smarter Analyst
Vertex Pharmaceuticals Incorporated (VRTX) Rises 2.66% for December 31  Equities.com

Vertex Pharmaceuticals Incorporated is a Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases.

Equities.com
Douglass Winthrop Advisors LLC Has $256,000 Position in Vertex Pharmaceuticals Incorporated (VRTX)  Fairfield Current

Douglass Winthrop Advisors LLC trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.4% in the 4th quarter, according to its most ...

Fairfield Current
Crispr Therapeutics AG (NASDAQ:CRSP) Major Shareholder Vertex Pharmaceuticals (Europe Acquires 22,742 Shares  Fairfield Current

Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Vertex Pharmaceuticals (Europe acquired 22742 shares of the stock in a transaction that occurred ...

Fairfield Current
Recent Alteration: – Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX)  Nyse NewsToday

The Relative Strength Index (RSI) is a technical indicator used in the analysis of financial markets. It is intended to chart the current and historical strength or ...

Nyse NewsToday
Vertex Pharma (VRTX) Expands Current Partnership with X-Chem Inc.  StreetInsider.com

X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation ...

StreetInsider.com
Key Turning Points To Take Off: – Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX)  Nyse NewsToday

The Relative Strength Index (RSI) is a technical indicator used in the analysis of financial markets. It is intended to chart the current and historical strength or ...

Nyse NewsToday
Positive Prospects, But Probably: Vertex Pharmaceuticals Incorporated (VRTX)  NMSU Nеws

Raymond James rated the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)'s stock as a Mkt Perform in a research note published on Wednesday, ...

NMSU Nеws
Vertex Pharmaceuticals Incorporated (VRTX) Stock Having Attractive Number on Juicy Yield  Wallstreet Investorplace

Vertex Pharmaceuticals Incorporated (VRTX) struggling for active trader tendency of a security's returns to respond to swings in the market is vital to know for ...

Wallstreet Investorplace
Stock's Technical Analysis – Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)  Alpha Beta Stock

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stock encountered a rapid change of -0.28% in the last hour of Wednesday's trading session. The stock ...

Alpha Beta Stock
Institutions Continue To Be Top Holders in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)  MTL News

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)'s shares are under review with key ownership changing hands of late. Successful investors are typically ...

MTL News
Talking Numbers: Returns & Quant Update on Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Heineken NV (ENXTAM:HEIA)  Richland Standard

Today we are spotlighting shares of Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) and looking at how the firm stacks up in terms of valuation by the.

Richland Standard
Vertex Pharmaceuticals Incorporated (VRTX) Enterprise Valuation Touches 41568167.47  Martin Business Telegraph

Vertex Pharmaceuticals Incorporated (VRTX) presently has an EV or Enterprise Value of 41568167.47. The EV helps show how the market assigns value to a ...

Martin Business Telegraph
Brokerages Set Vertex Pharmaceuticals Incorporated (VRTX) Price Target at $202.33  Fairfield Current

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has received a consensus rating of “Buy” from the twenty-six brokerages that are presently covering the ...

Fairfield Current
The More you take Risk the more you earn: Vertex Pharmaceuticals Incorporated (VRTX)  Wallstreet Investorplace

Vertex Pharmaceuticals Incorporated (VRTX) closed the Friday at final price of $188.16 after traded 2214267 shares. The average volume was noted at ...

Wallstreet Investorplace
$1.04 EPS Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter  Fairfield Current

Brokerages expect that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will announce earnings of $1.04 per share for the current quarter, Zacks reports.

Fairfield Current
American Airlines Group Inc. (NasdaqGS:AAL), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) ROA & Quant Review  Martin Business Telegraph

There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka.

Martin Business Telegraph
CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals Inc. (VRTX) Reports FDA Fast Track Designation for CTX001 for Treatment of Sickle Cell Disease  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. CRISPR Therapeutics (NASDAQ: CRSP) and ...

StreetInsider.com
Jump In Or Stay Clear?: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)  News Room Alert

An important aspect of EPS that's often ignored is the capital that is required to generate the earnings (net income) in the calculation. Two companies could ...

News Room Alert
Healthcor Management LP Lowered Vertex Pharmaceuticals (VRTX) Holding by $27.53 Million as Shares Declined; Bonness Enterprises Has Trimmed Its Stake in Oracle (ORCL) by $765,000  The Hi New Ulm

Healthcor Management Lp decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 41.49% based on its latest 2018Q3 regulatory filing with the SEC.

The Hi New Ulm
Patience To Be Paid Off: Vertex Pharmaceuticals Incorporated (VRTX), Paychex, Inc. (PAYX)  The RNS Daily

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)'s beta now stands at 1.53 and when compared to its 200-day moving average and its 50-day moving ...

The RNS Daily
Consensus Rating Review for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)  Hawthorn Caller

Investors have the ability to track Wall Street analyst opinions in order to assist with stock research. Analysts often provide Buy, Sell, or Hold.

Hawthorn Caller
Eye-Catching Shares – Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)  Seekingfin

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stock experienced a change of -0.28% in final minutes of Wednesday's trading session. The stock ...

Seekingfin
Biotech Stock Vertex Leads In Cystic Fibrosis Treatments  Investor's Business Daily

Vertex is the IBD Stock Of The Day as the leading biotech stock broke out in higher-than-average volume. Vertex stock has been forming a double-bottom base.

Investor's Business Daily
Are Analysts Turning Critical? – Vertex Pharmaceuticals Incorporated (VRTX), Palo Alto Networks, Inc. (PANW)  Post Analyst

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) attracted a higher number of shares in volume with 1.97 million contracts traded on 20-Dec-18. However ...

Post Analyst
Equity Research Analyst’s Stock Ratings: Vertex Pharmaceuticals Incorporated (VRTX), Univar Inc. (UNVR)  Analyst Journal

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) tinted gains of +5.48% (+8.97 points) to US$172.7. The volume of 1.83 Million shares climbed up over an ...

Analyst Journal
Vertex Pharmaceuticals Incorporated (VRTX) to strike $198.64 in short term period  Voice Of Analysts

Vertex Pharmaceuticals Incorporated (VRTX) stock managed performance 8.95% over the last week and switched with performance of 8.62% throughout past ...

Voice Of Analysts
Noticeable Observation For Stock Investors:: Vertex Pharmaceuticals Incorporated, (NYSE: VRTX)  Nyse Nasdaq News

Notable Technical and Performance analysis of the Vertex Pharmaceuticals Incorporated stocks which belongs to US stocks Exchanges: ...

Nyse Nasdaq News
Johnston Asset Management Decreased Its Vertex Pharmaceuticals (VRTX) Position; Fred Alger Management Trimmed By $456,548 Its Svb Financial Group (SIVB) Holding  The FinExaminer

Johnston Asset Management Corp decreased Vertex Pharmaceuticals Inc (VRTX) stake by 1.53% reported in 2018Q3 SEC filing. Johnston Asset Management ...

The FinExaminer
Stock Have a Latest Story: Vertex Pharmaceuticals Incorporated (VRTX), Amkor Technology (AMKR)  News Stays On Track

Vertex Pharmaceuticals Incorporated (VRTX) Daily Performance: Vertex Pharmaceuticals Incorporated (VRTX) stock negotiated recent volume of 2251237 ...

News Stays On Track
First Financial Bank – Trust Division Upped Its Digital Rlty Tr (DLR) Stake by $2.71 Million as Share Value Declined; Vertex Pharmaceuticals (VRTX) Holder Healthcor Management LP Has Trimmed Its Position  The Yomi Blog

First Financial Bank – Trust Division increased its stake in Digital Rlty Tr Inc (DLR) by 405.31% based on its latest 2018Q3 regulatory filing with the SEC.

The Yomi Blog
Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $821.11 Million  Fairfield Current

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $821.11 million in sales for the current quarter, Zacks Investment Research ...

Fairfield Current
Book to Market Ratio For Vertex Pharmaceuticals Incorporated (VRTX) Placed Under Scrutiny as it hits 0.061076  Martin Business Telegraph

Vertex Pharmaceuticals Incorporated (VRTX) is yielding a market ratio of 0.061076. The book to market ratio is a relative valuation ratio which divides.

Martin Business Telegraph
Vertex Pharmaceuticals (VRTX) Share Value Declined While Biondo Investment Advisors Upped Stake; Varian Medical Systems (VAR) Shareholder Willis Investment Counsel Has Cut Its Holding by $1.68 Million as Stock Value Rose  The FinReviewer

Biondo Investment Advisors Llc increased its stake in Vertex Pharmaceuticals Inc (VRTX) by 22.55% based on its latest 2018Q3 regulatory filing with the SEC.

The FinReviewer
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) Sales Change of 0.23235 YoY  Wheaton Journal

Investors looking to take advantage of cash heavy shares, they might look first to the cash flow of a company, and how fast that is growing. Vertex.

Wheaton Journal
Vertex Pharmaceuticals Incorporated (VRTX) Is Taking Advantages of Yield Performance on Stock Price  Wallstreet Investorplace

Vertex Pharmaceuticals Incorporated (VRTX) struggling for active trader tendency of a security's returns to respond to swings in the market is vital to know for ...

Wallstreet Investorplace
Soaring beliefs: TD Ameritrade Holding Corporation (AMTD), Vertex Pharmaceuticals Incorporated (VRTX)  FinBulletin

TD Ameritrade Holding Corporation (NASDAQ: AMTD)'s stock value took a rollercoaster ride since the start of the recent year, with the year-to-date change of ...

FinBulletin
Vertex Pharmaceuticals Incorporated (VRTX) Stock Creates Investor's Concerns  Investing News Update

Vertex Pharmaceuticals Incorporated (VRTX) stock price added 2.66% with the closing value of $165.71 during Monday trading session. Along recent rise drift, ...

Investing News Update
Vertex Pharmaceuticals Incorporated (VRTX) Shares Sold by Paloma Partners Management Co  Modern Readers

Paloma Partners Management Co decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 81.3% during the 3rd quarter, according ...

Modern Readers
How the government shutdown is affecting biotech companies  MarketWatch

The government shutdown is affecting the U.S. Food and Drug Administration's ability to review new drugs, putting biotech companies in a tough spot.

MarketWatch
Quantitative Investment Management Raised Vertex Pharmaceuticals (VRTX) Holding by $2.61 Million; Enterprise Products Partners LP (EPD) Shareholder Argyll Research Cut Position by $40.05 Million  The Moveefy

Argyll Research Llc decreased its stake in Enterprise Products Partners Lp (EPD) by 11.64% based on its latest 2018Q3 regulatory filing with the SEC.

The Moveefy
As Stanley Black & Decker (SWK) Market Valuation Declined, Shareholder Vanguard Group Has Decreased Holding; Btg Pactual Global Asset Management LTD Has Decreased Vertex Pharmaceuticals (VRTX) Stake as Valuation Declined  The FinHeadLines

Btg Pactual Global Asset Management Ltd decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 67.03% based on its latest 2018Q3 regulatory filing with ...

The FinHeadLines
Trust Asset Management Has Lowered Stake in Enterprise Products Partners Partnership Shares (EPD) as Shares Declined; Cim Investment Mangement Stake in Vertex Pharmaceuticals (VRTX) Has Decreased by $315,840 as Valuation Declined  The Moveefy

Cim Investment Mangement Inc decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 49.92% based on its latest 2018Q3 regulatory filing with the SEC.

The Moveefy
Analysts See $0.20 EPS for TTM Technologies, Inc. (TTMI); Kepos Capital LP Trimmed Vertex Pharmaceuticals (VRTX) Holding  EN Digest

Analysts expect TTM Technologies, Inc. (NASDAQ:TTMI) to report $0.20 EPS on February, 6.They anticipate $0.20 EPS change or 50.00% from last quarter's ...

EN Digest
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Growing Rapidly, But Expectations Still High  Hawthorn Caller

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have been experiencing an accelerated earnings and sales growth over the past 5 years.

Hawthorn Caller
Buckeye Partners LP Unit LTD Partn (BPL) Holder Summit Equities Raised Its Holding by $2.86 Million as Share Value Declined; As Vertex Pharmaceuticals (VRTX) Share Value Declined, Bb Biotech Ag Lowered Holding by $5.76 Million  The FinExaminer

Summit Equities Inc increased its stake in Buckeye Partners LP Unit Ltd Partn (BPL) by 0.46% based on its latest 2018Q3 regulatory filing with the SEC. Summit ...

The FinExaminer
American Century Companies Upped Holding in Vertex Pharmaceuticals (VRTX); Wealthtrust Axiom Has Upped International Business Machs (IBM) Stake by $620,308  The FinExaminer

American Century Companies Inc increased its stake in Vertex Pharmaceuticals Inc (VRTX) by 2.04% based on its latest 2018Q3 regulatory filing with the SEC.

The FinExaminer
Vertex Pharmaceuticals (VRTX) EPS Estimated At $0.71; Mader & Shannon Wealth Management Lowered By $373,296 Its Jp Morgan Chase & Co Com (JPM) Stake  The FinReviewer

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.71 EPS on January, 30.They anticipate $0.39 EPS change or 121.88% from ...

The FinReviewer
Nuance Communications (NUAN) Holder Bridgewater Associates LP Cut Its Position by $555,849; Synovus Financial Raised Vertex Pharmaceuticals (VRTX) Holding by $1.72 Million; Shares Declined  The FinReviewer

Bridgewater Associates Lp decreased its stake in Nuance Communications Inc (NUAN) by 55.73% based on its latest 2018Q3 regulatory filing with the SEC.

The FinReviewer
How to spot risky biotech companies and six to avoid now  MarketWatch

Steer clear of cash-hungry biotech companies with dire funding needs.

MarketWatch
Vertex Pharmaceuticals Waits to Hit the Triple  Motley Fool

The biotech's current cystic fibrosis drugs are still growing well.

Motley Fool
Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation  The Motley Fool

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be the poster child of pipeline success in the biotech world. The company's cystic fibrosis (CF) ...

The Motley Fool
AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated  The Motley Fool

At the moment, treatment options for cystic fibrosis are limited to drugs marketed by Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), but a deep-pocketed ...

The Motley Fool
Vertex Pharmaceuticals Is A Solid Buy In 2018  Seeking Alpha

Vertex Pharmaceuticals continues to be a leading player in the cystic fibrosis space in 2018. The company is focused on advancing its research pipeline in the ...

Seeking Alpha
Vertex Pharmaceuticals (VRTX) Stock Price, Financials and News | The Future 50  Fortune

Vertex Pharmaceuticals is #7 on the 2017 Fortune 500 list. Find the latest news, stock prices and financial information for Vertex Pharmaceuticals on ...

Fortune
Long-Term Outlook For Vertex  Seeking Alpha

VRTX has outperformed several of its peers and competitors in 2018, with a price up 20% in the last 6 months. More bullish news has come out of its tech ...

Seeking Alpha
3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks  Motley Fool

The market isn't fully appreciating just how much more room this biotech has to grow.

Motley Fool
Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue  Motley Fool

Vertex Pharmaceuticals' (NASDAQ:VRTX) launch of its newest cystic fibrosis drug, Symdeko, continues to progress well, driving second-quarter revenue growth.

Motley Fool
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals  The Motley Fool

Ascending and descending? That might be how some investors view Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals ...

The Motley Fool
Vertex Pharmaceuticals CFO bids adieu  Seeking Alpha

Vertex Pharmaceuticals ([[VRTX]] -2.2%) announces that Thomas Graney will resign as Chief Financial Officer ((CFO)) effective immediately. Ian F. Smith, Ex.

Seeking Alpha
Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV  Motley Fool

When it comes to treating cystic fibrosis (CF), you have Vertex Pharmaceuticals (NASDAQ:VRTX) and, well, that's pretty much it. However, Galapagos ...

Motley Fool
Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today  The Motley Fool

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were trading 14% higher as of 11 a.m. EDT on Friday. The nice jump for the biotech stock ...

The Motley Fool
Vertex Pharma's triplet therapy for CF successful in two late-stage studies  Seeking Alpha

Vertex Pharmaceuticals (VRTX) announces the successful outcome of two Phase 3 clinical trials evaluating the triple combination of VX-659, a next-generatio.

Seeking Alpha
Vertex Pharmaceuticals: Opportunities And Dangers  Seeking Alpha

Vertex has a high P/E ratio of 214, so is priced to perfection. Vertex saw a big dip in 2016 after Incivek revenue dropped. Successful expansion in and beyond c.

Seeking Alpha
Vertex Pharma's VX-150 successful in mid-stage neuropathy study  Seeking Alpha

Results from a Phase 2 clinical trial evaluating Vertex Pharmaceuticals' (VRTX) VX-150 in patients with pain caused by small fiber neuropathy showed a trea.

Seeking Alpha
Eli Lilly CEO Predicts 2019 Will Be Big Year for Biotech Acquisitions  GuruFocus.com

Eli Lilly CEO Predicts 2019 Will Be Big Year for Biotech Acquisitions, Stocks: LLY,LOXO,BAYN,MRK,ILMN,BMY,CELG,ACOR,BIIB,ALNY,SNY, release date:Jan ...

GuruFocus.com
Long-Term Outlook For Vertex Pharmaceuticals: October 13, 2018  Seeking Alpha

Vertex Pharmaceuticals has been a rising star in the biotech field, with excellent price action for well over a year now (excluding the latest dip). The dip is.

Seeking Alpha
Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock  Motley Fool

CRISPR Therapeutics might lead its start-up peers, but its collaboration partner is the better stock to buy.

Motley Fool
Vertex Pharmaceuticals: Analysts Say Buy This 'Growth Champion'  Seeking Alpha

Vertex's stock has been on the rise. Wall Street analysts are positive on this biotech story. Is VRTX winning the cystic fibrosis monopoly?

Seeking Alpha
By The Numbers: Is Vertex A Buy?  Seeking Alpha

Vertex is producing rapid revenue growth and expanding profitability. Valuation is not excessive when considering the company's growth potential. Winners tend ...

Seeking Alpha
Vertex Pharmaceuticals Inc (VRTX) Q3 2018 Earnings Conference Call Transcript  Motley Fool

VRTX earnings call for the period ending September 30, 2018.

Motley Fool
Vertex Hits Again in CF as First Three-Drug Combo Succeeds in Phase 3  Xconomy

Vertex Pharmaceuticals already dominates the landscape of treatments for cystic fibrosis, and its position got even better today. Vertex (NASDAQ: ]) said.

Xconomy
Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?  Yahoo Finance

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ...

Yahoo Finance
Vertex Pharma (VRTX) Announces Health Canada Grants Market Authorization for ORKAMBI for Children with CF  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Vertex Pharmaceuticals Incorporated (Nasdaq: ...

StreetInsider.com
Orphan Diseases Market 2019 :Global Industry Analysis Novartis, Bristol-Myers Squibb, Roche  reportsherald.com

Global Orphan Diseases Market 2019-2024. The worldwide Orphan Diseases Market report provides a detailed analysis of the cutting-edge dynamics of the ...

reportsherald.com
Should Vertex Pharmaceuticals (VRTX) Be On Your Radar Now?  Zacks.com

Vertex Pharmaceuticals (VRTX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

Zacks.com
Vertex Pharmaceuticals (VRTX) Q2 2018 Results - Earnings Call Transcript  Seeking Alpha

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)Q2 2018 Earnings CallJuly 25, 2018 4:30 pm ETExecutivesMichael Partridge - Vertex Pharmaceuticals, Inc.Jeffrey ...

Seeking Alpha
Vertex Hits The Top, As Competitor Galapagos Doesn't Impress In Cystic Fibrosis Study  Seeking Alpha

Vertex Pharmaceuticals' stock traded higher by 14% after Galpago's phase 2 cystic fibrosis study didn't impress. The C2 corrector from Galpagos, on top of ...

Seeking Alpha
Vertex Pharma's Orkambi OK'd in Canada for young children  Seeking Alpha

Health Canada approves Vertex Pharmaceuticals' (VRTX) ORKAMBI (lumacaftor/ivacaftor) for children aged 2-5 years old with cystic fibrosis who harbor two co.

Seeking Alpha
Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock  The Motley Fool

Vertex Pharmaceuticals (NASDAQ:VRTX) started the year on a high note with the approval of its new cystic fibrosis drug, Symdeko. It posted solid first-quarter ...

The Motley Fool
Genomics Partners Vertex Pharmaceuticals, Closes €28M Fundraising  Labiotech.eu

Genomics, a company using machine learning to analyze genetic data, is partnering with precision medicine specialists Vertex Pharmaceuticals to develop new ...

Labiotech.eu
Vertex Pharma's Symkevi OK'd in Europe  Seeking Alpha

The European Commission approves Vertex Pharmaceuticals' (VRTX) SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor), for the treatment of ...

Seeking Alpha
5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call  The Motley Fool

You've probably heard by now that Vertex Pharmaceuticals (NASDAQ:VRTX) once again hit the ball out of the park with its 2018 first-quarter results.

The Motley Fool
Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't  Boston Business Journal

The Waltham startup is taking on the market giant Vertex Pharmaceuticals by developing an injection that targets the 10 percent of patients that Vertex and ...

Boston Business Journal
CRISPR, Vertex launch first company-backed gene editing trial in humans  Boston Business Journal

Cambridge biotech CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals have launched the first company-sponsored study of a gene editing drug ...

Boston Business Journal
Vertex Pharmaceuticals Heads Toward An Important Tipping Point  Seeking Alpha

VRTX showed good sales growth in Q1, beating the Street, with rising operational profits despite heavy R&D spending. I like the company's chance to dominate ...

Seeking Alpha
Vertex CFO jumps to Atlas-backed startup Generation Bio  Boston Business Journal

One of Vertex Pharmaceuticals' top executives is leaving the company after just a year to join Generation Bio, an Atlas Venture-backed biotech startup focused ...

Boston Business Journal
Benzinga's Top Upgrades, Downgrades For January 2, 2019  Benzinga

Top Upgrades Baird upgraded SunTrust Banks, Inc. (NYSE: STI) from Neutral to Outperform. SunTrust shares fell 1 percent to $49.96 in pre-market ...

Benzinga
Vertex Hums Along as AbbVie Snatches Up a Rival's CF Drugs for $45M  Xconomy

AbbVie has just reworked a long-running deal with partner Galapagos NV, paying $45 million up front---a small sum for the pharmaceutical giant---to gain.

Xconomy
Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound?  Zacks.com

Vertex Pharmaceuticals (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com
Looking for a Growth Stock? Why It is Time to Focus on Vertex Pharmaceuticals (VRTX)  Zacks.com

Vertex Pharmaceuticals (VRTX) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks ...

Zacks.com
Vertex Pharmaceuticals (VRTX) Q1 2018 Results - Earnings Call Transcript  Seeking Alpha

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)Q1 2018 Earnings CallApril 26, 2018 4:30 pm ETExecutivesMichael Partridge - Vertex Pharmaceuticals, ...

Seeking Alpha
7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock  The Motley Fool

Vertex Pharmaceuticals (NASDAQ:VRTX) achieved something in 2017 that few stocks did: It more than doubled. At the beginning of this year, I picked Vertex as ...

The Motley Fool
Boston's Vertex Has Taken A Roller Coaster Ride To Profitability  WBUR

Editor's Note: Vertex is a WBUR underwriter but has no role in editorial decisions. Sign up here to get occasional updates from WBUR's ongoing coverage of ...

WBUR
 

Vertex Pharmaceuticals Videos

We Are Vertex: Our Story
18:14:15
We Are Vertex: Our Story
Vertex Pharmaceuticals
20:19:18
Vertex Pharmaceuticals
Vertex Pharmaceuticals & Team IMPACT
13:42:16
Vertex Pharmaceuticals & Team IMPACT
Vertex Pharmaceuticals Gives Back
20:47:57
Vertex Pharmaceuticals Gives Back
Working at Vertex Pharmaceuticals - May 2018
17:18:27
Working at Vertex Pharmaceuticals - May 2018
Biotech's Next Big Thing: Vertex
19:14:19
Biotech's Next Big Thing: Vertex
(VRTX) Vertex Pharmaceuticals Inc.
17:10:11
(VRTX) Vertex Pharmaceuticals Inc.
Why Abbvie, Vertex and Biogen are the Best Pharma Stocks to Buy
16:34:29
Why Abbvie, Vertex and Biogen are the Best Pharma Stocks to Buy
10th Annual Vertex Day of Service
13:57:41
10th Annual Vertex Day of Service
✍Vertex Pharma jumps 14% after rival releases poor cystic fibrosis drug results
03:16:55
✍Vertex Pharma jumps 14% after rival releases poor cystic fibrosis drug results
 

Vertex Pharmaceuticals Images

Vertex Pharmaceuticals Receives a Buy from Jefferies ...
Vertex Pharmaceuticals Receives a Buy from Jefferies ...
Vertex Receives European Approval for KALYDECO (ivacaftor ...
Vertex Receives European Approval for KALYDECO (ivacaftor ...
Vertex Logo | RealWire RealResource
Vertex Logo | RealWire RealResource
Vertex Pharmaceuticals: "SELLING HOPE IS EASY IN AN ...
Vertex Pharmaceuticals: "SELLING HOPE IS EASY IN AN ...
CF Patients See Benefits in Vertex’s Triple-Combination Trials
CF Patients See Benefits in Vertex’s Triple-Combination Trials
CFOs on the Move: Week Ending Sept. 8
CFOs on the Move: Week Ending Sept. 8
Merck KGaA pays $230M for four Vertex cancer programs ...
Merck KGaA pays $230M for four Vertex cancer programs ...
VERTEX PHARMACEUTICALS – Edufinanzas
VERTEX PHARMACEUTICALS – Edufinanzas
Xconomy: Vertex Bags Concert’s Rival CF Drug For $160M ...
Xconomy: Vertex Bags Concert’s Rival CF Drug For $160M ...
Sphere of influence - Irena Itskova
Sphere of influence - Irena Itskova
 

Vertex Pharmaceuticals WebSites

 

Vertex Pharmaceuticals Wiki

Vertex Pharmaceuticals, Inc. is an American pharmaceutical company based in Boston, Massachusetts.Vertex was founded in 1989 by Joshua Boger and Kevin J. Kinsella. Vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.By 2004, its product pipeline focused on viral infections, inflammatory and autoimmune disorders, and cancer. It maintains headquarters in South Boston, Massachusetts, and two research facilities, in San Diego, California, and Oxford, England. The company's beginnings were profiled by Barry Werth in the 1994 book The Billion-Dollar Molecule and its further development in his 2014 book, The Antidote: Inside the World of New Pharma. In 2009, the company had about 1,800 employees, including 1,200 in the Boston area.In January 2014, Vertex completed its move from Cambridge, Massachusetts to Boston, Massachusetts, and took residence in a new, $800 million complex. Located on the South Boston waterfront, it will mark the first time in the company's history that all of the roughly 1,200 Vertex employees in the Greater Boston area will be working together.Since late 2011, when Jeffrey M. Leiden joined Vertex as CEO, Vertex has ranked among the top 15 best performing companies on the Standard & Poor's 500. Vertex shares increased 250 percent in the same period. Vertex posted only one annual profit since it was founded in 1989.